Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:KZIA

Novogen 11/7/2025 Earnings Report

Novogen logo
$13.45 +0.61 (+4.75%)
Closing price 04:00 PM Eastern
Extended Trading
$13.06 -0.39 (-2.86%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Novogen EPS Results

Actual EPS
-$6.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novogen Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novogen Announcement Details

Quarter
Date
11/7/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Novogen Earnings Headlines

Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst
April 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4895704-kazia-therapeutics-diverse-cancer-pipeline-still-needs-a-major-catalyst
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
April 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-strengthens-scientific-leadership-with-appointment-of-dr-sudha-rao-as-chief-scientific-officer-to-lead-next-generation-oncology-platform-302742491.html
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
April 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-oncology-platform-with-first-in-class-setdb1-inhibitor-drug-development-platform-302740954.html
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
January 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-compelling-preclinical-and-translational-data-for-nuclear-pd-l1-degrader-ndl2-302674710.html
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
January 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-encouraging-preliminary-clinical-responses-in-ongoing-phase-1b-study-of-paxalisib-in-late-stage-metastatic-triple-negative-breast-cancer-302670593.html
See More Novogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email.

About Novogen

Novogen (NASDAQ:KZIA) (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide. The company benefits from strategic partnerships and licensing arrangements designed to advance its lead programs through clinical trials while expanding its preclinical pipeline into additional tumor types. Novogen’s global footprint enables access to diverse patient populations and fosters collaborations in neuroscience and oncology research.

Under the leadership of Chief Executive Officer Dr. Daniel Goldstein, Novogen continues to prioritize the rapid development of its clinical candidates through regulatory milestones. The management team combines expertise in medicinal chemistry, clinical development, and regulatory affairs to streamline translational research and engage with key opinion leaders. Through ongoing clinical trials and data readouts, Novogen aims to demonstrate the safety and efficacy of its novel small molecule therapies and to establish strategic partnerships for commercialization.

View Novogen Profile
Earnings Tools